



Figure S2. BRCA2 deficiency enhances the sensitivity of cancer cells towards PARP inhibition or TRAIL. SYBR green proliferation assay of BRCA2 deficient CAPAN1 and the respective syngenic BRCA2/CIN cell line complemented to express wild-type BRCA2 (A, B), homozygous BRCA2 knockout colorectal cancer cell line DLD1 termed DLD1 BRCA2^{KO} vs. wild-type DLD1 cells (C, D), BRCA2 deficient HCT116 and BRCA2 proficient SW620 (E, F) after 6 days of treatment with olaparib or TRAIL in increasing concentrations. All experiments were performed at least in duplicates with error bars representing SEM from independent experiments. B, D, F: IC50 values obtained for each compound tested and their ratio, defined as IC50 in the context of BRCA2 deficiency divided by IC50 in the context of BRCA2 proficiency.